Open Payments

KENNETH S SHARLIN

Type
Physician · Allopathic & Osteopathic Physicians / Internal Medicine
Where
OZARK, MO
NPI
1790749182
Received
$145,364 in 818 records, 2019 to 2025 ($38,447 general, $106,917 research)
As principal investigator
$4,185,937 of research payments to others in 183 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment95$3,115
2025Research payment2$13,800
2024General payment130$3,685
2023General payment174$3,398
2023Research payment7$13,267
2022General payment140$5,499
2022Research payment2$4,235
2021General payment120$13,792
2021Research payment4$75,615
2020General payment111$8,281
2019General payment33$675

By company

CompanyRecordsAmountYears
Eli Lilly and Company6$79,9652021–2023
Amneal Pharmaceuticals LLC6$13,8662024–2025
PFIZER INC.51$12,9382023–2025
Allergan, Inc.32$6,7672020–2021
Biohaven Pharmaceuticals, Inc.36$5,8052020–2021
Biogen, Inc.56$3,9842019–2024
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.26$3,2612022
E.R. Squibb & Sons, L.L.C.4$2,4582024–2025
ABBVIE INC.27$2,1152021–2025
Titan Surgical Group, LLC1$1,9232020
Novartis Pharmaceuticals Corporation59$1,3072019–2025
Neurocrine BioSciences, Inc.46$1,1352022–2025
Lilly USA, LLC63$1,0432019–2025
Supernus Pharmaceuticals, Inc.64$7652019–2025
Novartis Pharma AG1$7032021
Teva Pharmaceuticals USA, Inc.26$6592019–2025
EMD Serono, Inc.34$6082022–2025
Celgene Corporation31$5662022–2025
Eisai Inc.22$5462020–2025
Lundbeck LLC28$5102020–2025
Medtronic, Inc.6$4852023
HARMONY BIOSCIENCES LLC21$4372020–2023
GENZYME CORPORATION13$4022019–2025
JAZZ PHARMACEUTICALS INC.15$3202020–2025
Tanabe Pharma America, Inc.14$2472020–2025
Amgen Inc.11$2312019–2022
Janssen Pharmaceuticals, Inc7$2282021–2022
Genentech USA, Inc.13$2192022–2025
MDD US Operations, LLC10$1872022–2025
Mallinckrodt Hospital Products Inc.8$1772022–2025
Sumitomo Pharma America, Inc.8$1642023
TG Therapeutics, Inc.5$1142024–2025
Vanda Pharmaceuticals Inc.4$1042025
Amylyx Pharmaceuticals, Inc.5$992023–2024
Corium, LLC9$952022–2023
KYOWA KIRIN, INC.5$872022–2024
SK Life Science, Inc.4$822023–2025
ARGENX US, INC.4$772023–2025
IMPEL PHARMACEUTICALS INC.5$702022–2023
Alexion Pharmaceuticals, Inc.3$592020–2024
ACADIA Pharmaceuticals Inc3$592022–2025
Sunovion Pharmaceuticals Inc.4$552022
GE HEALTHCARE3$542022–2024
ANI Pharmaceuticals, Inc.3$532022–2025
Takeda Pharmaceuticals U.S.A., Inc.2$522023–2025
Avanir Pharmaceuticals, Inc.3$522022
UCB, Inc.3$482020–2021
Janssen Biotech, Inc.1$372025
Otsuka America Pharmaceutical, Inc.2$332025
LivaNova USA, Inc.1$222024

By nature of payment

NatureRecordsAmount
Research payment15$106,917
Food and Beverage775$14,693
Compensation for services other than consulting, including serving as faculty or as a speaker at a v9$13,900
Travel and Lodging12$4,860
Consulting Fee1$2,825
Education6$2,168

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-18GENZYME CORPORATION$29Food and BeverageIn-kind items and services2025
2025-12-09Janssen Biotech, Inc.$37Food and BeverageIn-kind items and services2025
2025-12-09Vanda Pharmaceuticals Inc.$27Food and BeverageIn-kind items and servicesPONVORY Drug, MULTIPLE SCLEROSIS2025
2025-12-04Genentech USA, Inc.$16Food and BeverageIn-kind items and servicesOcrevus Zunovo Biological, Immunology2025
2025-12-02PFIZER INC.$17Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-12-02TG Therapeutics, Inc.$13Food and BeverageIn-kind items and servicesBRIUMVI Drug, Immunology2025
2025-11-21ABBVIE INC.$21Food and BeverageIn-kind items and servicesVYALEV Drug, NEUROSCIENCE2025
2025-11-18EMD Serono, Inc.$16Food and BeverageCash or cash equivalent2025
2025-11-17Supernus Pharmaceuticals, Inc.$14Food and BeverageIn-kind items and servicesQelbree Drug, VILOXAZINE HYDROCHLORIDE2025
2025-11-17Supernus Pharmaceuticals, Inc.$13Food and BeverageIn-kind items and servicesQelbree Drug, VILOXAZINE HYDROCHLORIDE2025
2025-11-12Eisai Inc.$24Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-11-12Amneal Pharmaceuticals LLC$20Food and BeverageIn-kind items and servicesCREXONT Drug, NEUROLOGY2025
2025-11-10Otsuka America Pharmaceutical, Inc.$18Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2025
2025-11-03Mallinckrodt Hospital Products Inc.$22Food and BeverageIn-kind items and servicesACTHAR Biological, IMMUNOLOGY2025
2025-10-31ABBVIE INC.$18Food and BeverageIn-kind items and servicesVYALEV Drug, NEUROSCIENCE2025
2025-10-30SK Life Science, Inc.$25Food and BeverageIn-kind items and services2025
2025-10-28Celgene Corporation$15Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2025
2025-10-27PFIZER INC.$10Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-10-27PFIZER INC.$4Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-10-24ABBVIE INC.$16Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-10-16GENZYME CORPORATION$84Food and BeverageIn-kind items and services2025
2025-10-14GENZYME CORPORATION$30Food and BeverageIn-kind items and services2025
2025-10-13ANI Pharmaceuticals, Inc.$15Food and BeverageIn-kind items and servicesPURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA2025
2025-10-10Tanabe Pharma America, Inc.$14Food and BeverageIn-kind items and servicesRadicava Drug, Not Applicable2025
2025-10-07Vanda Pharmaceuticals Inc.$18Food and BeverageIn-kind items and servicesPONVORY Drug, MULTIPLE SCLEROSIS2025
2025-09-25Eisai Inc.$19Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-09-25Otsuka America Pharmaceutical, Inc.$15Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2025
2025-09-15Teva Pharmaceuticals USA, Inc.$15Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-09-09Takeda Pharmaceuticals U.S.A., Inc.$28Food and BeverageIn-kind items and servicesHYQVIA Biological, IMMUNOLOGY2025
2025-09-08ARGENX US, INC.$19Food and BeverageIn-kind items and servicesVYVGART HYTRULO Drug, Neurology2025
2025-09-03Amneal Pharmaceuticals LLC$15Food and BeverageIn-kind items and servicesCREXONT Drug, NEUROLOGY2025
2025-08-26Vanda Pharmaceuticals Inc.$28Food and BeverageIn-kind items and servicesPONVORY Drug, MULTIPLE SCLEROSIS2025
2025-08-25PFIZER INC.$12Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-08-14Eisai Inc.$21Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-08-12Teva Pharmaceuticals USA, Inc.$16Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-08-05Celgene Corporation$18Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2025
2025-08-04Novartis Pharmaceuticals Corporation$21Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2025
2025-07-31Eisai Inc.$20Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-07-24GENZYME CORPORATION$36Food and BeverageIn-kind items and services2025
2025-07-24Novartis Pharmaceuticals Corporation$21Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2025
2025-07-23Lilly USA, LLC$20Food and BeverageIn-kind items and servicesKISUNLA Drug, Neuroscience2025
2025-07-22Amneal Pharmaceuticals LLC$6,900Research paymentCash or cash equivalentCREXONT Drug, NEUROLOGYIPX203-401-232025
2025-07-22Amneal Pharmaceuticals LLC$6,900Research paymentCash or cash equivalentCREXONT Drug, NEUROLOGYIPX203-401-232025
2025-07-22E.R. Squibb & Sons, L.L.C.$1,177Travel and LodgingIn-kind items and services2025
2025-07-22Neurocrine BioSciences, Inc.$24Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2025
2025-07-21Amneal Pharmaceuticals LLC$11Food and BeverageIn-kind items and servicesCREXONT Drug, NEUROLOGY2025
2025-07-15GENZYME CORPORATION$36Food and BeverageIn-kind items and services2025
2025-07-14Teva Pharmaceuticals USA, Inc.$19Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-07-08EMD Serono, Inc.$14Food and BeverageCash or cash equivalent2025
2025-07-03Genentech USA, Inc.$29Food and BeverageIn-kind items and servicesOcrevus Zunovo Biological, Immunology2025
2025-06-26Eisai Inc.$32Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-06-17PFIZER INC.$5Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-06-16Genentech USA, Inc.$15Food and BeverageIn-kind items and servicesOcrevus Zunovo Biological, Immunology2025
2025-06-11Lilly USA, LLC$21Food and BeverageIn-kind items and servicesKISUNLA Drug, Neuroscience2025
2025-06-05Novartis Pharmaceuticals Corporation$30Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2025
2025-06-04Vanda Pharmaceuticals Inc.$29Food and BeverageIn-kind items and servicesPONVORY Drug, MULTIPLE SCLEROSIS2025
2025-06-02Mallinckrodt Hospital Products Inc.$22Food and BeverageIn-kind items and servicesACTHAR Biological, IMMUNOLOGY2025
2025-05-28PFIZER INC.$13Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-05-27Teva Pharmaceuticals USA, Inc.$19Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-05-21Eisai Inc.$22Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-05-20Novartis Pharmaceuticals Corporation$23Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2025
2025-05-19ACADIA Pharmaceuticals Inc$20Food and BeverageIn-kind items and servicesNUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS2025
2025-05-09Lundbeck LLC$17Food and BeverageCash or cash equivalentVYEPTI Biological, NEUROLOGY2025
2025-05-02ABBVIE INC.$14Food and BeverageIn-kind items and servicesUBRELVY Drug, NEUROSCIENCE2025
2025-04-28ACADIA Pharmaceuticals Inc$20Food and BeverageIn-kind items and servicesNUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS2025
2025-04-24PFIZER INC.$20Food and BeverageIn-kind items and servicesZAVZPRET Drug, PAIN2025
2025-04-22EMD Serono, Inc.$17Food and BeverageCash or cash equivalent2025
2025-04-21Teva Pharmaceuticals USA, Inc.$17Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-04-18PFIZER INC.$9Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-04-17Eisai Inc.$30Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-04-15TG Therapeutics, Inc.$27Food and BeverageIn-kind items and servicesBRIUMVI Drug, Immunology2025
2025-04-11Genentech USA, Inc.$16Food and BeverageIn-kind items and servicesOcrevus Zunovo Biological, Immunology2025
2025-04-02Novartis Pharmaceuticals Corporation$21Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2025
2025-04-01Neurocrine BioSciences, Inc.$17Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2025
2025-03-28Genentech USA, Inc.$30Food and BeverageIn-kind items and servicesOcrevus Zunovo Biological, Immunology2025
2025-03-27TG Therapeutics, Inc.$23Food and BeverageIn-kind items and servicesBRIUMVI Drug, Immunology2025
2025-03-25Eisai Inc.$18Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-03-24Lundbeck LLC$22Food and BeverageCash or cash equivalentVYEPTI Biological, NEUROLOGY2025
2025-03-13EMD Serono, Inc.$18Food and BeverageCash or cash equivalent2025
2025-03-13PFIZER INC.$4Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-03-10SK Life Science, Inc.$20Food and BeverageIn-kind items and services2025
2025-03-06MDD US Operations, LLC$24Food and BeverageIn-kind items and servicesGocovri Drug, AMANTADINE2025
2025-03-04Novartis Pharmaceuticals Corporation$20Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2025
2025-03-03Teva Pharmaceuticals USA, Inc.$18Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-02-25TG Therapeutics, Inc.$24Food and BeverageIn-kind items and servicesBRIUMVI Drug, Immunology2025
2025-02-24PFIZER INC.$12Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-02-24PFIZER INC.$5Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-02-11Lilly USA, LLC$25Food and BeverageIn-kind items and servicesKISUNLA Drug, Neuroscience2025
2025-02-04Novartis Pharmaceuticals Corporation$21Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2025
2025-01-30Eisai Inc.$23Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-01-28EMD Serono, Inc.$20Food and BeverageCash or cash equivalent2025
2025-01-27Teva Pharmaceuticals USA, Inc.$16Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-01-21JAZZ PHARMACEUTICALS INC.$25Food and BeverageIn-kind items and servicesXYWAV Drug, NEUROLOGY2025
2025-01-17ABBVIE INC.$13Food and BeverageIn-kind items and servicesUBRELVY Drug, NEUROSCIENCE2025
2025-01-15PFIZER INC.$12Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-01-13Lilly USA, LLC$14Food and BeverageIn-kind items and servicesEMGALITY Drug, Neuroscience2025
2025-01-09Celgene Corporation$18Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2025
2024-12-19Neurocrine BioSciences, Inc.$2Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2024
2024-12-18Neurocrine BioSciences, Inc.$18Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2024
2024-12-17EMD Serono, Inc.$22Food and BeverageCash or cash equivalent2024
2024-12-05Novartis Pharmaceuticals Corporation$28Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2024
2024-11-26Eisai Inc.$26Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2024
2024-11-25EMD Serono, Inc.$19Food and BeverageCash or cash equivalent2024
2024-11-25Lundbeck LLC$15Food and BeverageCash or cash equivalentVYEPTI Biological, NEUROLOGY2024
2024-11-25Lundbeck LLC$2Food and BeverageCash or cash equivalentVYEPTI Biological, NEUROLOGY2024
2024-11-22Genentech USA, Inc.$17Food and BeverageIn-kind items and servicesOcrevus Zunovo Biological, Immunology2024
2024-11-21Neurocrine BioSciences, Inc.$25Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2024
2024-11-18PFIZER INC.$20Food and BeverageIn-kind items and servicesZAVZPRET Drug, PAIN2024
2024-11-12Novartis Pharmaceuticals Corporation$23Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2024
2024-11-12PFIZER INC.$13Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2024
2024-11-07Teva Pharmaceuticals USA, Inc.$18Food and BeverageIn-kind items and servicesAustedo XR Drug, Central Nervous System2024
2024-11-05MDD US Operations, LLC$13Food and BeverageIn-kind items and servicesGocovri Drug, AMANTADINE2024
2024-11-01Lundbeck LLC$18Food and BeverageCash or cash equivalentVYEPTI Biological, NEUROLOGY2024
2024-10-29Eisai Inc.$28Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2024
2024-10-24Eisai Inc.$22Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2024
2024-10-24Lilly USA, LLC$14Food and BeverageIn-kind items and servicesEMGALITY Drug, Neuroscience2024
2024-10-21Tanabe Pharma America, Inc.$17Food and BeverageIn-kind items and servicesRADICAVA Drug, AMYOTROPHIC LATERAL SCLEROSIS2024
2024-10-18EMD Serono, Inc.$14Food and BeverageCash or cash equivalent2024
2024-10-14PFIZER INC.$5Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2024
2024-10-09Novartis Pharmaceuticals Corporation$23Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2024
2024-10-03Genentech USA, Inc.$15Food and BeverageIn-kind items and servicesOcrevus Zunovo Biological, Immunology2024
2024-10-02GENZYME CORPORATION$27Food and BeverageIn-kind items and services2024
2024-09-30Teva Pharmaceuticals USA, Inc.$18Food and BeverageIn-kind items and servicesAustedo XR Drug, Central Nervous System2024
2024-09-24EMD Serono, Inc.$16Food and BeverageCash or cash equivalent2024
2024-09-23Lilly USA, LLC$16Food and BeverageIn-kind items and servicesEMGALITY Drug, Neuroscience2024
2024-09-19PFIZER INC.$12Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2024
2024-09-18Eisai Inc.$25Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2024
2024-09-13ABBVIE INC.$16Food and BeverageIn-kind items and servicesUBRELVY Drug, NEUROSCIENCE2024
2024-09-10Lundbeck LLC$13Food and BeverageCash or cash equivalentVYEPTI Biological, NEUROLOGY2024
2024-09-09TG Therapeutics, Inc.$24Food and BeverageIn-kind items and servicesBRIUMVI Drug, Immunology2024
2024-09-05PFIZER INC.$11Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2024
2024-09-04Novartis Pharmaceuticals Corporation$23Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2024
2024-09-04Novartis Pharmaceuticals Corporation$7Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2024
2024-09-03Celgene Corporation$23Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2024
2024-08-28Neurocrine BioSciences, Inc.$3Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2024
2024-08-27Lilly USA, LLC$23Food and BeverageIn-kind items and servicesKISUNLA Drug, Neuroscience2024
2024-08-27Neurocrine BioSciences, Inc.$22Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2024
2024-08-21Lilly USA, LLC$16Food and BeverageIn-kind items and servicesEMGALITY Drug, Neuroscience2024
2024-08-20Eisai Inc.$25Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2024
2024-08-19Teva Pharmaceuticals USA, Inc.$17Food and BeverageIn-kind items and servicesAustedo XR Drug, Central Nervous System2024
2024-08-15Mallinckrodt Hospital Products Inc.$31Food and BeverageIn-kind items and servicesACTHAR Biological, IMMUNOLOGY2024
2024-08-14Tanabe Pharma America, Inc.$15Food and BeverageIn-kind items and servicesRADICAVA Drug, AMYOTROPHIC LATERAL SCLEROSIS2024
2024-08-10MDD US Operations, LLC$22Food and BeverageIn-kind items and servicesGocovri Drug, AMANTADINE2024
2024-08-10EMD Serono, Inc.$18Food and BeverageCash or cash equivalent2024
2024-08-01Lilly USA, LLC$6Food and BeverageIn-kind items and servicesEMGALITY Drug, Neuroscience2024
2024-07-31EMD Serono, Inc.$23Food and BeverageCash or cash equivalent2024
2024-07-29Genentech USA, Inc.$17Food and BeverageIn-kind items and servicesEnspryng Biological, Immunology2024
2024-07-24Neurocrine BioSciences, Inc.$22Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2024
2024-07-23Alexion Pharmaceuticals, Inc.$27Food and BeverageIn-kind items and services2024
2024-07-22Lilly USA, LLC$3Food and BeverageIn-kind items and servicesKISUNLA Drug, Neuroscience2024
2024-07-19PFIZER INC.$9Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2024
2024-07-17Eisai Inc.$25Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2024
2024-07-16Celgene Corporation$14Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2024
2024-07-15Lilly USA, LLC$21Food and BeverageIn-kind items and servicesEMGALITY Drug, Neuroscience2024
2024-07-12Biogen, Inc.$16Food and BeverageIn-kind items and servicesQALSODY Drug, Neurology2024
2024-07-11Lundbeck LLC$16Food and BeverageCash or cash equivalentVYEPTI Biological, NEUROLOGY2024
2024-07-09Novartis Pharmaceuticals Corporation$23Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2024
2024-06-27EMD Serono, Inc.$17Food and BeverageCash or cash equivalent2024
2024-06-24ARGENX US, INC.$16Food and BeverageIn-kind items and servicesVYVGART Drug, Immunology2024
2024-06-21Neurocrine BioSciences, Inc.$22Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2024
2024-06-20Neurocrine BioSciences, Inc.$5Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2024
2024-06-17Lilly USA, LLC$14Food and BeverageIn-kind items and servicesEMGALITY Drug, Neuroscience2024
2024-06-13Lilly USA, LLC$19Food and BeverageIn-kind items and servicesAMYVID Drug, Neuroscience2024
2024-06-13PFIZER INC.$10Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2024
2024-06-10Novartis Pharmaceuticals Corporation$26Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2024
2024-06-04Tanabe Pharma America, Inc.$15Food and BeverageIn-kind items and servicesRADICAVA Drug, AMYOTROPHIC LATERAL SCLEROSIS2024
2024-06-03PFIZER INC.$16Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2024
2024-05-30LivaNova USA, Inc.$22Food and BeverageIn-kind items and servicesVNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology2024
2024-05-28Genentech USA, Inc.$16Food and BeverageIn-kind items and servicesOcrevus Biological, Immunology2024
2024-05-23Amneal Pharmaceuticals LLC$19Food and BeverageIn-kind items and servicesONGENTYS Drug, NEUROLOGY2024
2024-05-22Lilly USA, LLC$21Food and BeverageIn-kind items and servicesEMGALITY Drug, Neuroscience2024
2024-05-20Teva Pharmaceuticals USA, Inc.$19Food and BeverageIn-kind items and servicesAustedo XR Drug, Central Nervous System2024
2024-05-20Lundbeck LLC$15Food and BeverageCash or cash equivalentVYEPTI Biological, NEUROLOGY2024
2024-05-17PFIZER INC.$10Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2024
2024-05-14Novartis Pharmaceuticals Corporation$32Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2024
2024-05-09Neurocrine BioSciences, Inc.$26Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2024
2024-05-08EMD Serono, Inc.$16Food and BeverageCash or cash equivalent2024
2024-05-07KYOWA KIRIN, INC.$20Food and BeverageIn-kind items and servicesNourianz Drug, Adenosine A2A Receptors2024
2024-05-01Celgene Corporation$24Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2024
2024-04-25GE HEALTHCARE$19Food and BeverageIn-kind items and services2024
2024-04-25Abbott Laboratories$14Food and BeverageIn-kind items and servicesETERNA Device, Neuromodulation2024
2024-04-23Novartis Pharmaceuticals Corporation$21Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2024
2024-04-23ANI Pharmaceuticals, Inc.$16Food and BeverageIn-kind items and servicesPURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA2024
2024-04-19PFIZER INC.$5Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2024
2024-04-18EMD Serono, Inc.$20Food and BeverageCash or cash equivalent2024
2024-04-17Lilly USA, LLC$20Food and BeverageIn-kind items and servicesAMYVID Drug, Neuroscience2024
2024-04-17PFIZER INC.$7Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2024
2024-04-15Lundbeck LLC$16Food and BeverageCash or cash equivalentVYEPTI Biological, NEUROLOGY2024
2024-04-11Neurocrine BioSciences, Inc.$25Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2024
2024-04-11Neurocrine BioSciences, Inc.$22Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2024
2024-04-10Neurocrine BioSciences, Inc.$130Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2024
2024-04-10Neurocrine BioSciences, Inc.$6Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2024
2024-04-08Mallinckrodt Hospital Products Inc.$13Food and BeverageIn-kind items and servicesACTHAR Biological, IMMUNOLOGY2024
2024-04-04Teva Pharmaceuticals USA, Inc.$19Food and BeverageIn-kind items and servicesAustedo XR Drug, Central Nervous System2024
2024-03-29E.R. Squibb & Sons, L.L.C.$778Travel and LodgingIn-kind items and services2024
2024-03-29E.R. Squibb & Sons, L.L.C.$328Travel and LodgingIn-kind items and services2024
2024-03-29E.R. Squibb & Sons, L.L.C.$173Food and BeverageCash or cash equivalent2024
2024-03-26Novartis Pharmaceuticals Corporation$19Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2024
2024-03-25Lilly USA, LLC$16Food and BeverageIn-kind items and servicesEMGALITY Drug, Neuroscience2024
2024-03-20KYOWA KIRIN, INC.$19Food and BeverageIn-kind items and servicesNourianz Drug, Adenosine A2A Receptors2024

The latest 200 records of 818.

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-31ABBVIE INC.INFINITE RESEARCH GROUP LLC$1,440A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safe2025
2025-12-22GENZYME CORPORATIONSharlin Health And Neurology$10,779A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-12-11ABBVIE INC.INFINITE RESEARCH GROUP LLC$660Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2025
2025-11-24PFIZER INC.SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$4,110PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT2025
2025-11-12Hoffmann-La Roche LimitedINFINITE RESEARCH GROUP LLC$2,593A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple S2025
2025-11-05Eli Lilly and CompanyINFINITE RESEARCH GROUP LLC$59,012AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY35412025
2025-11-04GENZYME CORPORATIONINFINITE RESEARCH GROUP LLC$70,469Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima2025
2025-10-24GENZYME CORPORATIONINFINITE RESEARCH GROUP LLC$14,002Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima2025
2025-10-17ModernaTX, Inc.Sharlin Health & Neurology$66A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 12025
2025-10-09ABBVIE INC.INFINITE RESEARCH GROUP LLC$100Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Ch2025
2025-10-08Hoffmann-La Roche LimitedINFINITE RESEARCH GROUP LLC$1,730A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple S2025
2025-10-08Hoffmann-La Roche LimitedINFINITE RESEARCH GROUP LLC$7,102A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple S2025
2025-10-08Hoffmann-La Roche LimitedINFINITE RESEARCH GROUP LLC$3,500A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple S2025
2025-09-04ABBVIE INC.INFINITE RESEARCH GROUP LLC$4,266Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2025
2025-09-03GENZYME CORPORATIONSharlin Health And Neurology$12,905An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa2025
2025-08-25GENZYME CORPORATIONSharlin Health And Neurology$7,173A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-08-06ModernaTX, Inc.Sharlin Health & Neurology$624A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 12025
2025-08-06ModernaTX, Inc.Sharlin Health & Neurology$12,486A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 12025
2025-08-06ModernaTX, Inc.Sharlin Health & Neurology$957A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 12025
2025-07-29PFIZER INC.SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$2,549PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIM2025
2025-07-02ModernaTX, Inc.Sharlin Health & Neurology$17A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 12025
2025-07-02ModernaTX, Inc.Sharlin Health & Neurology$66A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 12025
2025-06-25E.R. Squibb & Sons, L.L.C.SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$18,338A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Kar2025
2025-05-27Eli Lilly and CompanySHARLIN HEALTH AND NEUROLOGY LLC$56ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2025
2025-04-28GENZYME CORPORATIONSharlin Health And Neurology$14,336A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-04-14GENZYME CORPORATIONSharlin Health And Neurology$10,350A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2025
2025-03-06ABBVIE INC.SHARLIN HLTH NEUROSCIENCE RESH CNTR$366Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2025
2025-03-05Eli Lilly and CompanySHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$17,147AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY35412025
2025-02-24GENZYME CORPORATIONSharlin Health And Neurology$5,008A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa2025
2025-02-24GENZYME CORPORATIONSharlin Health And Neurology$9,320A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa2025
2025-02-05ABBVIE INC.SHARLIN HLTH NEUROSCIENCE RESH CNTR$366Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2025
2025-01-27GENZYME CORPORATIONSharlin Health And Neurology$2,036A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-01-21Eli Lilly and CompanySHARLIN HEALTH AND NEUROLOGY LLC$8,055ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2025
2025-01-16Eli Lilly and CompanySHARLIN HEALTH AND NEUROLOGY LLC$1,146AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY35412025
2025-01-13GENZYME CORPORATIONSharlin Health And Neurology$9,817Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima2025
2025-01-02ABBVIE INC.SHARLIN HLTH NEUROSCIENCE RESH CNTR$1,686Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2025
2024-12-31ABBVIE INC.SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$1,4403110-305-002 Ph3 Pivotal Peds Post Approval - PMR (M21-265)2024
2024-12-18Eli Lilly and CompanySHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$3,600LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH 2024
2024-12-17Novartis Pharmaceuticals CorporationSharlin Health And Neurology$19An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat2024
2024-12-04ABBVIE INC.SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$366Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2024
2024-12-04Eli Lilly and CompanySHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$15,000AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY35412024
2024-12-03GENZYME CORPORATIONSharlin Health And Neurology$1,913A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-11-12GENZYME CORPORATIONSharlin Health And Neurology$901An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa2024
2024-11-12GENZYME CORPORATIONSharlin Health And Neurology$6,749An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa2024
2024-11-12GENZYME CORPORATIONSharlin Health And Neurology$1,913A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-11-06ABBVIE INC.SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$365Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2024
2024-11-06Hoffmann-La Roche LimitedSHARLIN HEALTH AND NEUROLOGY LLC$16,008Fen Ph II RMS2024
2024-10-28GENZYME CORPORATIONSharlin Health And Neurology$9,211Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima2024
2024-10-28Eli Lilly and CompanySHARLIN HEALTH AND NEUROLOGY LLC$109LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH 2024
2024-09-04GENZYME CORPORATIONSharlin Health And Neurology$2,680Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima2024
2024-09-04GENZYME CORPORATIONSharlin Health And Neurology$11,400An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa2024
2024-09-04GENZYME CORPORATIONSharlin Health And Neurology$9,500An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa2024
2024-09-04GENZYME CORPORATIONSharlin Health And Neurology$10,350A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2024
2024-09-04GENZYME CORPORATIONSharlin Health And Neurology$12,000Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima2024
2024-09-03ABBVIE INC.SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$366Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2024
2024-08-19GENZYME CORPORATIONSharlin Health And Neurology$4,000Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima2024
2024-08-15PFIZER INC.SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$2,544PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT2024
2024-08-12GENZYME CORPORATIONSharlin Health And Neurology$12,178Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima2024
2024-08-01ABBVIE INC.SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$2,052Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2024
2024-07-29GENZYME CORPORATIONSharlin Health And Neurology$5,360Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima2024
2024-07-25Eli Lilly and CompanySHARLIN HEALTH AND NEUROLOGY LLC$1,888AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY35412024
2024-07-22GENZYME CORPORATIONSharlin Health And Neurology$2,036A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-07-03ABBVIE INC.SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$630Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2024
2024-07-03Hoffmann-La Roche LimitedSHARLIN HEALTH AND NEUROLOGY LLC$16,334Fen Ph II RMS2024
2024-06-10GENZYME CORPORATIONSharlin Health And Neurology$1,913A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-06-05ABBVIE INC.SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$6,705Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Ch2024
2024-06-05ABBVIE INC.SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$4,022Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2024
2024-05-28GENZYME CORPORATIONSharlin Health And Neurology$1,248Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima2024
2024-05-23PFIZER INC.SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$836PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT2024
2024-05-08ABBVIE INC.SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$2,621Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2024
2024-04-22GENZYME CORPORATIONSharlin Health And Neurology$4,564Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima2024
2024-04-04ABBVIE INC.SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$3,815Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Ch2024
2024-04-04ABBVIE INC.SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$2,315Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2024
2024-03-11GENZYME CORPORATIONSharlin Health And Neurology$3,040Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima2024
2024-03-11GENZYME CORPORATIONSharlin Health And Neurology$8,861A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-03-07ABBVIE INC.SHARLIN HEALTH & NEUROLOGY LLC$732Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2024
2024-03-04GENZYME CORPORATIONSharlin Health And Neurology$14,800A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa2024
2024-02-22PFIZER INC.SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER$675PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT2024
2024-02-20GENZYME CORPORATIONSharlin Health And Neurology$13,800Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima2024
2024-02-12GENZYME CORPORATIONSharlin Health And Neurology$8,861A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-02-05GENZYME CORPORATIONSharlin Health And Neurology$10,796Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima2024
2024-02-01ABBVIE INC.SHARLIN HEALTH & NEUROLOGY LLC$2,418Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2024
2024-01-31Eli Lilly and CompanySHARLIN HEALTH AND NEUROLOGY LLC$2,047ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2024
2024-01-09Eli Lilly and CompanySHARLIN HEALTH AND NEUROLOGY LLC$278,682ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2024
2024-01-04ABBVIE INC.SHARLIN HEALTH & NEUROLOGY LLC$1,686Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2024
2024-01-04ABBVIE INC.SHARLIN HEALTH & NEUROLOGY LLC$231Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Ch2024
2024-01-03GENZYME CORPORATIONSharlin Health And Neurology$11,199A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2024
2024-01-03Biogen, Inc.SHARLIN HEALTH AND NEUROLOGY LLC$162,712A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Bene2024
2023-12-31ABBVIE INC.SHARLIN HEALTH NEUROSCIENCE RESEARCH$250Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Ch2023
2023-12-22Hoffmann-La Roche LimitedSHARLIN HEALTH AND NEUROLOGY LLC$14,420Fen Ph II RMS2023
2023-12-18GENZYME CORPORATIONSharlin Health And Neurology$1,913A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2023
2023-12-04ABBVIE INC.SHARLIN HEALTH & NEUROLOGY LLC DB$1,677Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Ch2023
2023-12-04ABBVIE INC.SHARLIN HEALTH & NEUROLOGY LLC DB$4,453Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2023
2023-11-22Hoffmann-La Roche LimitedSHARLIN HEALTH AND NEUROLOGY LLC$1,588Fen Ph II RMS2023
2023-11-20GENZYME CORPORATIONSharlin Health And Neurology$8,000A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2023
2023-11-16PFIZER INC.1$990PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT2023
2023-10-30GENZYME CORPORATIONSharlin Health And Neurology$30,630A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-10-23GENZYME CORPORATIONSharlin Health And Neurology$16,176A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-10-03GENZYME CORPORATIONSharlin Health And Neurology$2,150A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2023
2023-10-03GENZYME CORPORATIONSharlin Health And Neurology$1,913A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2023

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Christian CountyOzark city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Ozark, MO, county Christian County, MO, state Missouri; placed by its city name.

MeasurePlace (city or town)
Ozark, MO
County
Christian County, MO
State
Missouri
Population B0100322,41792,9156,191,814
Population, 2020 census P121,28488,8426,154,913
Median age B0100233.839.239.0
Under 18 B0100127.9%25.1%22.3%
65 and over B0100114.6%16.7%17.9%
Households B110018,40835,1422,508,227
Foreign born B050024.1%2.6%4.5%
Median household income B19013$74,182$83,437$70,702
Median family income B19113$85,938$97,213$91,360
Per capita income B19301$32,257$39,805$39,695
Poverty rate B1700112.6%8.2%12.6%
Unemployment rate B230254.3%3.4%4.0%
Civilian labor force B2302511,31646,7633,120,639
Mean commute (minutes) B0801323.525.523.5
Bachelor's degree or higher B1500330.7%32.7%32.4%
Housing units B250018,74236,6432,825,287
Owner-occupied B2500362.6%75.9%68.1%
Renters B2500337.4%24.1%31.9%
Median home value B25077$254,800$274,900$230,300
Median gross rent B25064$1,097$1,058$1,033
White, not Hispanic B0300285.4%90.4%76.3%
Black B030021.5%0.7%10.9%
Hispanic or Latino B030026.0%3.8%5.2%
Asian B030020.8%0.8%2.1%
American Indian and Alaska Native B030020.1%0.2%0.2%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Ozark, MO.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.